Executive Director, Global Program Manager

About Kardigan

Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.

It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.

Led by Tassos Gianakakos, Jay Edelberg, M.D., Ph.D., and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.

We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.

At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families, we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in being authentic—leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn, we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.

These values are the foundation of our work, empowering us to make a real difference, every day.

Executive Director, Global Program Manager

About the Team

Kardigan’s Program Management team is the operational engine of our Global Program Teams — connecting strategy to execution, functions to outcomes, and teams to purpose. Global Program Managers (GPMs) hold the integrated view of each program at all times — scientific, operational, financial, and interpersonal — owning the Integrated Development & Commercialization Plan (IDCP) as the plan of record, integrated timelines and critical path, program risk governance, governance packages and executive communication, and the meeting design and team practices that keep cross-functional teams healthy and decisive.

How programs are governed at Kardigan

Every program runs two governance bodies. The Global Program Team (GPT) owns the whole asset — the integrated strategy and the plan of record, which we call the Integrated Development & Commercialization Plan. The Global Clinical Team (GCT) owns the clinical program and the Clinical Development Plan that rolls up into it. Above them, the Executive Committee approves asset strategy and Monthly Portfolio Strategy (MPS) approves the plan of record and material changes to it. Below them, five function-led sub-teams do the delivery work. The Global Program Manager is one of only three roles that sit on both governance bodies, which is what makes this a program leadership role rather than a coordination one.

Job Overview

Kardigan is seeking an Executive Director, Global Program Manager to act as the “COO” of a Global Program Team (GPT) for one of our late-stage programs, working hand-in-hand with the Global Program Head (GPH) to connect strategy to execution across the full development lifecycle — from ongoing late-stage development through regulatory submission and, in the event of approval, launch readiness and lifecycle management.

The initial assignment is the tonlamarsen (TLA) program. Tonlamarsen is an investigational, once-monthly, subcutaneous, liver-directed antisense oligonucleotide targeting hepatic angiotensinogen. The current strategy is to establish proof of concept in the Phase 2 KARDINAL-ASH trial by evaluating sustained blood pressure reduction in high-risk patients with established cardiovascular or kidney disease after a recent acute severe hypertension event. The program’s upcoming milestones — data readouts, health authority interactions, the Phase 3 decision and the cross-functional coordination required by the Ionis alliance — demand a program manager who has led late-phase development before and, ideally, has taken an asset through filing and launch.

This is a program leadership role, not a project coordination role. The Executive Director is a strategic partner to the GPH with deep, first-hand knowledge of how clinical, regulatory, CMC, medical and commercial workstreams interlock in late-phase development, regulatory submission and launch. The role leads through influence, holds the integrated view of the program at all times, and owns the machinery that makes the program run. As the program management function grows, the Executive Director will also mentor and develop Global Program Managers and help build Kardigan’s program management capability, processes and tools.

Essential Duties and Responsibilities

Strategic Program Leadership (hand-in-hand with the GPH)

• Serve as the GPH’s strategic partner: develop and stress-test program strategy, challenge assumptions, and translate strategy into executable integrated operating plans.
• Act as the primary integrator across GPT functions — Clinical Development, Regulatory, CMC, Nonclinical, Medical Affairs, Commercial, Finance and Legal — facilitating high-quality, timely decisions and resolving cross-functional dependencies, bottlenecks and trade-offs before they become program risks.
• Model shared accountability and a program-first mindset across the GPT and its sub-teams.

Governance Role on the Global Program Team and the Global Clinical Team

The Global Program Manager is one of only three roles that sit on both governance bodies. In practice that means:

• Run both rooms. Serve as a full-time core member of the GPT alongside the GPH, and hold a core seat on the GCT, which is co-chaired by the Clinical Development Lead and the Clinical Operations Program Lead. Own the agendas, circulate the pre-reads, keep the decision and action logs, and make sure every session ends with decisions, owners and dates. Under the charters this is the GPM's role rather than a co-chair's — they hold the chair as functional leaders and strategists; the mechanics sit with you.
• Be the connective tissue between the two bodies. Carry GPT taskings down to the GCT with the question, the decision it feeds and the date it is needed and carry GCT recommendations back up for endorsement. Hold the line on what decision-ready means: alternatives evaluated, functions consulted, disagreement named, and the implications for goals, budget, timelines and risk spelled out.
• Own the plan of record. Maintain the Integrated Development & Commercialization Plan as a living document and the single source of truth for program status, decisions and assumptions across both governance bodies and the five function-led sub-teams.
• Prepare what goes upward. Build the governance packages the GPH carries to the Executive Committee and to Monthly Portfolio Strategy and apply the threshold rule so that anything moving risk profile, timelines, cost or opportunity potential is escalated as a recommendation rather than an open question.
• Own how the team’s work. Apply RAPID decision rights so that every decision has a single Recommender and a single Decider. Own the program's charter and seat list, run the annual review and the team health assessment, and guard against the failure modes the charters name — re-litigating decisions, confusing decision rights, and escalating instead of solving.

Drug Development Expertise and the Integrated Development & Commercialization Plan (IDCP)

• Apply deep, first-hand late-phase drug development expertise — Phase 3 design and execution, regulatory submission, CMC readiness, launch readiness and lifecycle management — to identify risks and acceleration opportunities across the IDCP.
• Lead the development and evolution of the IDCP — the plan of record into which the Clinical Development Plan (from the GCT), the Integrated Evidence Plan (from the Medical Strategy Team) and the Integrated Product Strategy roll up: drive functional input, surface and resolve trade-offs, assess risk and build cross-functional alignment, and prepare the Integrated Development & Commercialization Plan for recommendation by the GPH to MPS.
• Lead program-level planning for health authority submissions (maintenance of the Investigational New Drug application, end-of-Phase 2 and pre-New Drug Application (NDA) interactions, and NDA planning and execution) in partnership with Regulatory Affairs and lead cross-functional launch-readiness planning in anticipation of potential approval.
• Coordinate program deliverables, data exchanges and obligations under the alliance agreement (Ionis for TLA) in partnership with Regulatory Affairs, Legal and functional leads, ensuring alliance commitments are tracked and reflected in integrated